A Phase I Study Of Docetaxel, Oxaliplatin, & Capecitabine (DOC) As First-Line Therapy of Patients With Locally Advanced or Metastatic Adenocarcinoma of Stomach and GE Junction

REFERENCES

• Alexander, H.R.; Kelsen, D.P.; Tepper, J.E. Cancer of the stomach. In Cancer: Principles and Practice of Oncology, V.T. DeVita, S. Hellman, S.A. Rosenberg (eds). Philadelphia, PA: Lppincott-Raven, 1997, 1021–1054.
   Google Scholar
• Ajani, J.A. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005, 10(Suppl. 3), 574–587.
   Google Scholar
• Cen, P.; Ajani, J.A. Medical treatment for advanced gastroesophageal adenocarcinoma. Curr Opin Gastroenterol 2007, 23, 631–635.
   PubMed Web of Science ®Google Scholar
• Ohtsu, A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008, 43, 256–264.
   PubMed Web of Science ®Google Scholar
• Catalano, V.; Labianca, R.; Beretta, G.D.; Gatta, G.; de Brand, F.; Van Custem, E. Gastric cancer. Crit Rev Oncol Hematol 2009, 71, 127–164.
   PubMed Web of Science ®Google Scholar
• Liu, G.; Franssen, E.; Fitch, M.I., Warner, E. Patients preference for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15, 110–115.
   PubMed Web of Science ®Google Scholar
• Miwa, M.; Ura, M.; Nishida, M.; Sawada, N.; Ishikawa, T.; Mori, K.; Shimma, N.; Umeda, I.; Ishitsuka, H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues. Eur J Cancer 1998, 34, 1274–1281.
   PubMed Web of Science ®Google Scholar
• Ishikawa, T.; Utoh, M.; Sawada, N.; Nishida, M.; Fukase, Y.; Sekiguchi, F.; Ishitsuka, H. Tumor selective delivery of 5-FU by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Bichem Pharmacol 1998, 55, 1091–1097.
   PubMed Web of Science ®Google Scholar
• Schüller, J.; Cassidy, J.; Dumont, E.; Roos, B.; Durston, S.; Banken, L.; Utoh, M.; Mori, K.; Weidekamm, E.; Reigner, B. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45, 291–297.
   PubMed Web of Science ®Google Scholar
• Takebayashi, Y.; Akiyama, S.; Akiba, S.; Yamada, K.; Miyadera, K.; Sumizawa, T.; Yamada, Y.; Murata, F.; Aikou, T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996, 88, 1110–1117.
   PubMed Web of Science ®Google Scholar
• Ishikawa, T.; Sekiguchi, F.; Fukase, Y.; Sawada, N.; Ishitsuka, H. Positive correlation between efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998, 58, 685–690.
   PubMed Web of Science ®Google Scholar
• Koizumi, W.; Saigenji, K.; Ujiie, S.; Terashima, M.; Sakata, Y.; Taguchi, T.; Clinical Study Group of Capecitabine. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003, 64, 232–236.
   PubMed Web of Science ®Google Scholar
• Ajani, J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006, 107, 221–231.
   PubMed Web of Science ®Google Scholar
• Dhillon, S.; Scott, L.J. Capecitabine: in advanced gastric and oesophagogastric cancer. Drugs 2007, 67, 601–610.
   PubMed Web of Science ®Google Scholar
• Sulkes, A.; Smyth, J.; Sessa, C.; Dirix, LY.; Vermorken, J.B.; Kaye, S.; Wanders, J.; Franklin, H.; LeBail, N.; Verweij, J. Taxotere in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994, 70, 380–383.
   PubMed Web of Science ®Google Scholar
• Einzig, A.; Neuberg, D.; Remick, S.C.; Karp, D.D.; O'Dwyer, P.J.; Stewart, J.A.; Benson, A.B. 3rd. Phase II trial of Taxotere in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996, 13, 87–93.
   PubMed Web of Science ®Google Scholar
• Graziono, F.; Catalano, V.; Baldelli, A.M.; Giordani, P.; Testa, E.; Lai, V.; Catalano, G.; Battelli, N.; Cascinu, S. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000, 11, 1263–1266.
   PubMed Web of Science ®Google Scholar
• Ajani, J.A. Docetaxel for gastric and esophageal carcinomas. Oncology 2002, 16, S89–S105.
   PubMed Web of Science ®Google Scholar
• Deeks, E.D.; Scott, L.J. Docetaxel: in gastric cancer. Drugs 2007, 67, 1893–1901.
   PubMed Web of Science ®Google Scholar
• Hainsworth, J.D. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004, 9, 538–545.
   PubMed Web of Science ®Google Scholar
• Rivera, E.; Meijia, J.A.; Arun, B.K.; Adinin, R.B.; Walters, R.S.; Brewster, A.; Broglio, K.R.; Yin, G.; Esmaeli, B.; Hortobagyi, G.N.; Valero, V. Phase 3 study comparing the use of docetaxel on an every 3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008, 112, 1455–1461.
   PubMed Web of Science ®Google Scholar
• Roth, A.D.; Maibach, R.; Martinelli, G.; Fazio, N.; Aapro, M.S.; Pagani, O.; Morant, R.; Borner, M.M.; Herrmann, R.; Honegger, H.; Cavalli, F.; Alberto, P.; Castiglione, M.; Goldhirsch A. Taxotere-platinol(TC): an effective drug combination in gastric cancer. Ann Oncol 2000, 11, 301–306.
   PubMed Web of Science ®Google Scholar
• Giordano, K.F.; Jatoi, A.; Stella, P.J.; Foster, N.; Tschetter, L.K.; Alberts, S.R.; Dakhil, S.R.; Mailliard, J.A.; Flynn, P.J.; Nikcevich, D.A. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006, 17, 652–656.
   PubMed Web of Science ®Google Scholar
• Raymond, E.; Faivre, S.; Woynarowski, J.M.; Chaney, S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998, 25, 4–12.
   PubMed Web of Science ®Google Scholar
• Louvet, C.; Andre, T.; Tigaud, J.M.; Gamelin, E.; Douillard, J.Y.; Brunet, R.; François, E.; Jacob, J.H.; Levoir, D.; Taamma, A.; Rougier, P.; Cvitkovic, E.; de Gramont, A. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002, 20, 4543–4548.
   PubMed Web of Science ®Google Scholar
• Borner, M.; Dietrich, D.; Stupp, R.; Morant, R.; Honegger, H.; Wernli, M.; Herrmann, R.; Pestalozzi, B.C.; Saletti, P.; Hanselmann, S.; Müller, S.; Brauchli, P.; Castiglione-Gertsch, M.; Goldhirsch, A.; Roth, A.D. Phase II study of capecitabine and oxaliplatin in first- and second line treatment of advanced or metastatic colorectal cancer. J Clin Oncol 2002, 20, 1759–1766.
   PubMed Web of Science ®Google Scholar
• Kim, D.Y.; Kim, J.H.; Lee, S.H.; Kim, T.Y.; Heo, D.S.; Bang, Y.J.; Kim, N.K. Phase II study of oxaliplatin, 5-fluorouracail and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003, 14, 383–387.
   PubMed Web of Science ®Google Scholar
• Cunningham, D.; Starling, N.; Rao, S.; Iveson, T.; Nicolson, M.; Coxon, F.; Middleton, G.; Daniel, F.; Oates, J.; Norman, A.R.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358, 36–46.
   PubMed Web of Science ®Google Scholar
• Raymond, E.; Buquet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic, E.; Allain, P.; Louvet, C.; Gespach, C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997, 8, 876–885.
   PubMed Web of Science ®Google Scholar
• Sawada, N.; Ishikawa, T.; Fukase, Y.; Nishida, M.; Yoshikubo, T.; Ishitsuka, H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xerografts. Clin Cancer Res 1998, 4, 1013–1019.
   PubMed Web of Science ®Google Scholar
• Yamamoto, S.; Kurebayashi, J.; Kurosumi, M.; Kunisue, H.; Otsuki, T.; Tanaka, K.; Sonoo, H. Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xerografts. Cancer Chemother Pharmacol 2001, 48, 283–288.
   PubMed Web of Science ®Google Scholar
• Wagner, A.D.; Grothe, W.; Haerting, J.; Kleber, G.; Grothey, A.; Fleig, W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24, 2903–2909.
   PubMed Web of Science ®Google Scholar
• Van Custem, E.; Moiseyenko, V.M.; Tjulandin, S.; Majlis, A.; Constenla, M.; Boni, C.; Rodrigues, A.; Fodor, M.; Chao, Y.; Voznyi, E.; Risse, M.L.; Ajani, J.A. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006, 24, 4991–4997.
   PubMed Web of Science ®Google Scholar
• Ajani, J.A.; Moiseyenko, V.M.; Tjulandin, S.; Majlis, A.; Constenla, M.; Boni, C.; Rodrigues, A.; Fodor, M.; Chao, Y.; Voznyi, E.; Awad, L.; Van Cutsem, E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric and gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007, 25, 3210–3216.
   PubMed Web of Science ®Google Scholar
• Ilson, D.H. Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 2007, 25, 3188–3190.
   PubMed Web of Science ®Google Scholar
• Roth, A.D.; Fazio, N.; Stupp, R.; Falk, S.; Bernhard, J.; Saletti, P.; Köberle, D.; Borner, M.M.; Rufibach, K.; Maibach, R.; Wernli, M.; Leslie, M.; Glynne-Jones, R.; Widmer, L.; Seymour, M.; de Braud, F. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubucin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007, 25, 3217–3223.
   PubMed Web of Science ®Google Scholar
• Evans, D.; Miner, T.; Akerman, P.; Millis, R.; Jean, M.; Kennedy, T.; Safran, H. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Oncol 2007, 30, 346–349.
   PubMed Web of Science ®Google Scholar